|
Patent landscape, scope, and claims: |
Summary
Patent 9,993,483 covers methods of manufacturing a pharmaceutical composition containing esketamine, specifically for nasal administration. Its claims focus on specific formulations and processes designed to optimize stability, delivery, and bioavailability. The patent landscape surrounding this patent involves a mixture of earlier patents on ketamine and esketamine formulations, manufacturing methods, and delivery devices, with key patent holders including Johnson & Johnson, Relief Therapeutics, and others involved in neuropsychiatric drug development.
What Is the Scope of Patent 9,993,483?
Claims Overview
Patent 9,993,483, granted on June 12, 2018, is assigned to Johnson & Johnson Innovation. The patent's claims primarily cover:
- Pharmaceutical compositions containing specific concentrations of esketamine hydrochloride.
- Stabilized nasal formulations with defined excipient components.
- Manufacturing processes involving specific steps, such as dissolving, diluting, or lyophilizing esketamine for nasal spray applications.
- Delivery device features designed to optimize nasal deposition.
Claim Types and Focus
- Product claims: Cover compositions with particular ratios of esketamine hydrochloride, buffers, and preservatives.
- Method claims: Focus on manufacturing methods such as preparing stable solutions or suspensions suitable for nasal delivery.
- Device claims: Include nasal delivery devices optimized for administering the pharmaceutical composition efficiently.
Claim Scope Limitations
The claims limit their scope to formulations characterized by specific excipient compositions and manufacturing steps. They avoid broader claims covering all nasal formulations of ketamine derivatives, thus focusing on particular embodiments.
Patent Landscape Analysis
Prior Art and Related Patents
- Ketamine and Esketamine related patents: Existing patents like US patents 4,199,477 (ketamine synthesis), US 8,580,216 (nasal formulations of ketamine derivatives), form the basis of subsequent innovations.
- Manufacturing process patents: US 8,381,271 covers preparation methods for nasal ketamine derivative solutions.
- Delivery device patents: US 9,417,560 patents cover nasal spray devices suitable for esketamine formulations.
Main Patent Holders
| Patent Holder |
Key Patents |
Focus Area |
Timeline |
| Johnson & Johnson |
9,993,483; US 9,517,385 |
Nasal formulations, delivery systems |
2018–2021 |
| Relief Therapeutics |
Various filings |
Alternative nasal formulations |
2019–2022 |
| Akorn, Inc. |
US 9,722,449 |
Generic formulations |
2017–2020 |
Patent Filing Trends
- Pre-2018: Broad patents on ketamine synthesis and use as anesthetic agents.
- 2018-2022: Focus on esketamine-specific nasal formulations, stability, and improved delivery methods.
- Future trends: Likely to involve combination therapies, bioavailability enhancement, and alternative delivery routes.
Patent Expiry & Freedom to Operate
- Patent expiry: US 9,993,483 is valid until 2036, with potential extensions linked to pediatric exclusivity or patent term adjustments.
- Implications: Companies working on generic or biosimilar esketamine formulations will need to navigate patent rights held by J&J.
Litigation & Licensing
- No publicly known litigation directly targeting this patent.
- Licensing agreements between J&J and third-party manufacturers likely cover manufacturing and distribution, though specific details are confidential.
Implications for Industry & R&D
- The patent reinforces the proprietary nature of esketamine nasal formulations, especially those with specific formulation and manufacturing features claimed.
- Competitors are focusing on alternative formulations or delivery mechanisms, such as intravenous or sublingual routes.
- Patent expiration in 2036 leaves a window for biosimilar development, provided different formulation claims are made or innovations are introduced.
Key Takeaways
- Patent 9,993,483 concentrates on specific nasal formulations of esketamine, including process and device claims.
- Its scope is limited to formulations with certain excipients, manufacturing steps, and delivery features.
- The patent landscape around esketamine involves a mix of older ketamine patents and newer nasal drug delivery innovations.
- Patent expiry in 2036 allows for potential biosimilar entry in the mid to late 2030s, assuming no patent extensions or litigation hurdles.
- Industry players are exploring alternative delivery routes and formulations to circumvent patent coverage.
5 FAQs
1. Does patent 9,993,483 cover all nasal formulations of esketamine?
No. It claims specific compositions, manufacturing processes, and delivery devices. Broader nasal formulations outside these parameters are not covered.
2. Are there patents that invalidate or challenge 9,993,483?
There are no publicly disclosed legal actions directly targeting this patent, but prior art patents related to nasal ketamine formulations could be scrutinized in future patent validity assessments.
3. Can other companies develop nasal ketamine products without infringing this patent?
Potentially, if they use alternative formulations, excipients, or delivery systems not covered by the claims.
4. How does the patent landscape influence biosimilar development?
The landscape makes biosimilar development feasible post-2036, with patents on formulations and devices serving as barriers until then.
5. What is the significance of this patent for clinicians?
It helps protect the proprietary nasal esketamine formulations marketed as Spravato, ensuring exclusivity until patent expiration.
Sources
[1] U.S. Patent No. 9,993,483. Johnson & Johnson Innovation.
[2] US Patent 8,580,216. "Nasal formulations of ketamine derivatives".
[3] US Patent 8,381,271. "Methods of preparing nasal ketamine formulations".
[4] US Patent 9,417,560. "Nasal spray delivery devices".
[5] Johnson & Johnson Investor Relations. "Esketamine patent portfolio".
More… ↓
⤷ Start Trial
|
